Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the 2023 Guggenheim Oncology Days conference in New York City on Thursday, February 9, 2023, at 1:35 p.m. ET.

A live audio webcast of the session may be accessed by visiting the Events page on the Investors & Media section of the Surface Oncology website. In addition, a replay of the webcast will be available on the company’s website following the presentation.

About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned programs; SRF388, a Phase 2 program which targets IL-27, and SRF114, a Phase 1 program which selectively depletes regulatory T cells in the tumor microenvironment via targeting CCR8. In addition, Surface has two partnerships with major pharmaceutical companies; a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit

Scott Young
(617) 865-3250

Primary Logo

Back to news